Chaperone-Mediated Proteostasis Disease Comparison

Migration, Crosslink

📖

Chaperone-Mediated Proteostasis Disease Comparison

active

wiki page Created: 2026-04-02T07:19:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-chaperone-mediated-prote

📖 Wiki Page

mechanism2782 wordssynced 2026-04-02

Chaperone-Mediated Proteostasis Disease Comparison

Overview

flowchart TD Chaperone_Mediated_Proteostasi["Chaperone-Mediated Proteostasis Disease Comparis"] Chaperone_Mediated_Proteostasi["Chaperone-Mediated"] Chaperone_Mediated_Proteostasi -->|"related to"| Chaperone_Mediated_Proteostasi style Chaperone_Mediated_Proteostasi fill:#81c784,stroke:#333,color:#000 Chaperone_Mediated_Proteostasi["cornerstone"] Chaperone_Mediated_Proteostasi -->|"related to"| Chaperone_Mediated_Proteostasi style Chaperone_Mediated_Proteostasi fill:#81c784,stroke:#333,color:#000 Chaperone_Mediated_Proteostasi["cellular"] Chaperone_Mediated_Proteostasi -->|"related to"| Chaperone_Mediated_Proteostasi style Chaperone_Mediated_Proteostasi fill:#81c784,stroke:#333,color:#000 style Chaperone_Mediated_Proteostasi fill:#4fc3f7,stroke:#333,color:#000

Chaperone-mediated proteostasis is a cornerstone of cellular protein quality control. The heat shock protein (Hsp) family — including Hsp70, Hsp40, Hsp90, and small Hsps — facilitates protein folding, prevents aggregation, and targets misfolded proteins for degradation via the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-dysfunction-neurodegeneration) or [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-dysfunction). This comparison examines how chaperone systems are altered across major neurodegenerative diseases.

Cross-Disease Comparison Matrix

...

Chaperone-Mediated Proteostasis Disease Comparison

Overview

Mermaid diagram (expand to render)

Chaperone-mediated proteostasis is a cornerstone of cellular protein quality control. The heat shock protein (Hsp) family — including Hsp70, Hsp40, Hsp90, and small Hsps — facilitates protein folding, prevents aggregation, and targets misfolded proteins for degradation via the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-dysfunction-neurodegeneration) or [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-dysfunction). This comparison examines how chaperone systems are altered across major neurodegenerative diseases.

Cross-Disease Comparison Matrix

| Chaperone System | Alzheimer's Disease | Parkinson's Disease | ALS/FTD | Huntington's Disease |
|-----------------|---------------------|-------------------|---------|---------------------|
| Hsp70 (HSPA family) | ↓ Hsp70 in AD brain; HSPA1L variants associated with risk | ↓ Hsp70 in SNc; PINK1/PARKIN regulate Hsp70 activity | Reduced Hsp70 in ALS motor cortex; C9orf72 hexanucleotide expansion affects chaperone network | Hsp70 induction protective in HD models; mutant HTT interferes with Hsp70 function |
| Hsp40 (DNAJ family) | DNAJA1, DNAJB1 reduced in AD; co-chaperone dysfunction | DNAJB6, DNAJB8 mutations cause PD; critical for α-synuclein folding | DNAJC proteins mutated in ALS (DNAJC7); TDP-43 affects J-domain function | DNAJC13 (RECA1) linked to HD; mutant HTT sequesters DNAJ proteins |
| Hsp90 (HSP90AA1) | Hsp90 inhibitors in AD clinical trials; targets tau, Aβ | Hsp90 inhibitors reduce α-synuclein toxicity | Hsp90 inhibition reduces SOD1, TDP-43 aggregation | Hsp90 inhibition reduces mutant HTT aggregation |
| Small Hsps (HspB family) | HspB2/B4 decreased in AD; αB-crystallin (HspB5) protects against tau | HspB5 (αB-crystallin) inhibits α-synuclein aggregation | HspB8 mutations cause ALS; HspB1 (Hsp27) protective | HspB8 reduces mutant HTT aggregation |
| Co-chaperones (TPR, J-domain) | BAG family, HOP, CHIP (STUB1) regulate Hsp70/90 | BAG proteins dysregulated in PD; PINK1 phosphorylates Hsp90 | STUB1 (CHIP) mutations cause ALS/FTD | BAG3 critical for autophagy in HD |

Disease-Specific Mechanisms

Alzheimer's Disease

In AD, the amyloid-β (Aβ) and tau pathologies are closely linked to chaperone system failure. The [amyloid cascade hypothesis](/mechanisms/amyloid-cascade) is modulated by chaperone activity:

Hsp70/Hsp90 axis: These chaperones regulate APP processing and Aβ secretion. Hsp90 inhibition reduces Aβ production by destabilizing BACE1, though clinical trials have shown limited efficacy ([NCT01227621](https://clinicaltrials.gov/NCT01227621), [NCT00591838](https://clinicaltrials.gov/NCT00591838))[@kim_hsp90_app].
Small Hsps: αB-crystallin (HspB5) binds tau and prevents its aggregation. Decreased HspB5 in AD brain correlates with neurofibrillary tangle burden.
CHIP (STUB1): This E3 ubiquitin ligase targets both tau and Aβ for degradation. STUB1 variants modify AD risk.

Parkinson's Disease

Chaperone systems are central to [α-synuclein](/proteins/alpha-synuclein) pathology in PD:

Hsp70 family: HSPA1L and HSPA8 (Hsc70) directly interact with α-synuclein, preventing its fibrillization. Hsp70 overexpression reduces α-synuclein toxicity in models[@dedmon_hsp70_asyn].
Hsp40 (DNAJB family): DNAJB6 and DNAJB8 are critical for α-synuclein disaggregation. DNAJB6 mutations cause familial PD[@funatsuki_dnajb6].
Hsp90: Forms complexes with α-synuclein and regulates its degradation via the proteasome.
Therapeutic targeting: Geldanamycin derivatives (Hsp90 inhibitors) have been tested in PD models ([NCT01031688](https://clinicaltrials.gov/NCT01031688)).

ALS/FTD

The [protein aggregation](/mechanisms/protein-aggregation-disease-comparison) seen in ALS and FTD involves TDP-43, SOD1, FUS, and C9orf72:

Hsp70/Hsp90: Critical for SOD1 folding. Hsp70 and Hsp90 inhibition accelerates mutant SOD1 aggregation.
DNAJ proteins: DNAJC7 and DNAJC19 mutations cause familial ALS. TDP-43 aggregation disrupts Hsp40 co-chaperone function.
CHIP (STUB1): Loss-of-function mutations in STUB1 cause ALS/FTD, impairing ubiquitin-dependent degradation[@chen_stub1_als].
BAG3: Critical for macroautophagy of aggregated proteins. BAG3 variants modify ALS progression.

Huntington's Disease

The [mutant huntingtin](/genes/huntingtin) (mHTT) protein actively disrupts chaperone networks:

Hsp70 recruitment: mHTT sequesters Hsp70, depleting the chaperone pool available for other proteins.
Hsp90 complexes: Hsp90 inhibition promotes mHTT clearance via autophagy ([NCT01454064](https://clinicaltrials.gov/NCT01454064))[@wang_htt_hsp90].
Small Hsps: HspB8 (Hsp22) and αB-crystallin reduce mHTT aggregation and are protective.
BAG3-mediated mitophagy: Critical for removing dysfunctional mitochondria in HD; BAG3 dysfunction exacerbates pathology.

Shared Mechanisms

All five diseases share chaperone system impairment:

Global Hsp70/Hsp90 downregulation — transcription factor HSF1 activation is reduced in aging and neurodegeneration

Co-chaperone sequestration — aggregated proteins sequester J-domain proteins, limiting their availability

Impaired protein turnover — chaperone-proteasome and chaperone-autophagy coupling is disrupted

Oxidative stress effects — oxidatively damaged proteins overwhelm chaperone capacity

Age-related decline — chaperone function naturally declines with age, accelerating pathology

Therapeutic Targets

| Target | Approach | Disease | Status |
|--------|----------|---------|--------|
| Hsp70 inducers | Arimoclomol, BGP-15 | ALS, PD | Clinical trials (NCT00706147, NCT02412535) |
| Hsp90 inhibitors | Geldanamycin derivatives | AD, PD, HD | Preclinical/Phase I |
| Hsp70/90 co-chaperones | BAG antagonists, J-domain proteins | All | Preclinical |
| Small Hsp modulators | αB-crystallin delivery | AD, PD | Preclinical |
| HSF1 activators | Geranylgeranylacetone | AD | Clinical trial (NCT03061929) |

Key Genes

Hsp70 family: [HSPA1A](/genes/hspa1a), [HSPA1B](/genes/hspa1b), [HSPA8](/genes/hspa8), HSPA1L
Hsp40 family: [DNAJB1](/genes/dnajb1), [DNAJB6](/genes/dnajb6), DNAJB8, DNAJC7, DNAJC19
Hsp90 family: [HSP90AA1](/genes/hsp90aa1), HSP90AB1
Small Hsps: [HSPB5](/genes/hspb5) (αB-crystallin), [HSPB8](/genes/hspb8), HSPB1
Co-chaperones: [STUB1](/genes/stub1) (CHIP), BAG1, BAG3, [HOP](/genes/hop)

Molecular Mechanisms of Chaperone Failure

Hsp70/HSPA Family

The Hsp70 family constitutes the primary chaperone system for protein folding in neurons. The canonical cycle involves Hsp70 binding to nascent or misfolded polypeptides through its substrate-binding domain (SBD), with ATP hydrolysis regulated by Hsp40 (DNAJ) co-chaperones. The ADP-bound state has high affinity for substrate; nucleotide exchange factors (NEFs) like BAG family members catalyze ADP release, allowing ATP rebinding and substrate release[@brehme_hsp70_aging].

In neurodegeneration, several interconnected mechanisms compromise Hsp70 function:

Transcriptional downregulation: HSF1 (Heat Shock Factor 1), the master regulator of Hsp70 transcription, becomes less responsive with age. Polyglutamine expansion proteins (mutant HTT, ataxins) directly bind HSF1 and sequester it, preventing transcriptional activation of Hsp70 genes.

Post-translational modification: Hsp70 is subject to oxidation, phosphorylation, and acetylation in disease states, reducing its chaperone activity. Mitochondrial damage generates ROS that modify cytosolic Hsp70.

Sequestration by aggregates: Aggregated proteins (Aβ, α-synuclein, TDP-43, mHTT) act as sink for Hsp70 and DNAJ proteins. The bound chaperones become unavailable for folding newly synthesized proteins, creating a cascade of proteostasis failure.

Impaired co-chaperone coordination: PINK1 phosphorylates Hsp90, regulating its interaction with client proteins in mitochondria[@leimkuhler_hsp70_pink1]. Loss of PINK1 (causing autosomal recessive PD) disrupts this coordination, leading to accumulation of misfolded mitochondrial proteins.

Neuronal vulnerability: Neurons have exceptionally high protein synthesis rates at synapses and lack the protein dilution mechanisms available to dividing cells, making them uniquely dependent on chaperone efficiency.

Hsp40/DNAJ Family

DNAJ proteins (Hsp40) are the largest chaperone co-chaperone family, with over 40 members in humans. They function primarily by:

J-domain function: All DNAJ proteins contain a characteristic J-domain that stimulates Hsp70 ATPase activity, converting Hsp70 to its high-affinity ADP-bound state
Substrate targeting: DNAJB1, DNAJB6, DNAJB8 actively deliver misfolded proteins to Hsp70 for refolding
Aggregate disaggregation: DNAJB6 and DNAJB8 are unique among Hsp40s in their ability to solubilize protein aggregates through collaboration with Hsp70

Mutations in DNAJB6 cause familial PD with late onset — the mutations impair the protein's disaggregation function, allowing α-synuclein to form toxic oligomers[@funatsuki_dnajb6]. DNAJC7 mutations cause autosomal dominant ALS, where the mutant protein fails to properly regulate Hsp70 client cycling for TDP-43[@blum_hsp40_dnajb6].

Hsp90/HSP90AA1 Family

Hsp90 is unique among chaperones in its specificity for a defined set of "client" proteins, many of which are signaling kinases and transcription factors. In neurodegeneration, Hsp90 has a paradoxical role — it stabilizes both beneficial (neurotrophic signaling proteins) and pathogenic (disease-causing mutant proteins) clients[@ravid_hsp90_brain].

In AD: Hsp90 forms stable complexes with both tau and Aβ. Hsp90 inhibitors reduce amyloid production by destabilizing BACE1 (β-secretase), but this approach has faced clinical challenges due to toxicity and insufficient CNS penetration.

In ALS: Hsp90 is critical for SOD1 stability — mutant SOD1 misfolds rapidly in the absence of Hsp90 protection. Hsp90 inhibition accelerates aggregation, paradoxically making it a challenging therapeutic target[@toubiana_hsp90_sod1].

Small Heat Shock Proteins (HspB Family)

The small Hsp family (12-42 kDa) functions differently from Hsp70/Hsp90 — they form large oligomers that bind early-stage aggregation intermediates, preventing fibril formation rather than promoting refolding.

HspB5 (αB-crystallin): Expressed at high levels in astrocytes and oligodendrocytes. In AD, αB-crystallin binds to phosphorylated tau and prevents its aggregation into neurofibrillary tangles. The decreased expression observed in AD brain may contribute to tangle formation[@johannesen_hspb5_tau].

HspB8 (Hsp22): Critical for macroautophagy of aggregate-prone proteins through its interaction with BAG3. Mutations in HSPB8 cause autosomal dominant ALS, impairing the clearance of TDP-43 aggregates. In HD, HspB8 overexpression reduces mHTT aggregation and is neuroprotective.

HSF1 and the Heat Shock Response

HSF1 Regulation

HSF1 is the master transcription factor for the heat shock response. Under normal conditions, HSF1 is kept inactive by association with Hsp90 and Hsp70 in a multi-chaperone complex. Proteostatic stress causes Hsp90/Hsp70 to release HSF1, which trimerizes, enters the nucleus, and activates transcription of Hsp genes and other protective genes[@morimoto_hsf1_aging].

In aging and neurodegeneration, HSF1 function declines through several mechanisms:

Chronic activation: Prolonged stress depletes the HSF1-negative-regulation chaperone pool, causing HSF1 to remain active but eventually become desensitized

Post-translational impairment: HSF1 becomes hyper-phosphorylated at inhibitory sites with age, reducing its transcriptional potency

Aggregate sequestration: Polyglutamine proteins directly bind HSF1 and trap it in the cytoplasm

Epigenetic changes: Age-related changes in chromatin structure reduce HSF1 target gene accessibility

Therapeutic Activation

Geranylgeranylacetone (GGA) is an HSF1 activator that has been tested in clinical trials for AD (NCT03061929)[@masser_geranylgeranylacetone]. It works by transiently depleting the Hsp90/Hsp70 pool, creating a temporary proteostatic stress that activates HSF1 without causing cell damage.

Arimoclomol is another HSF1 activator that extends survival in SOD1 mouse models and has progressed to clinical trials for ALS. It acts as a co-inducer of the heat shock response, amplifying the signal when HSF1 is partially activated.

Chaperone-Mediated Autophagy (CMA)

CMA Mechanism

Chaperone-mediated autophagy (CMA) is a selective degradation pathway where Hsc70 (HSPA8) recognizes KFERQ-like motifs in substrate proteins and delivers them to the lysosomal membrane for internalization through LAMP-2A receptors[@rodriguez_chaperone_autophagy].

Steps in CMA:

Hsc70 (constitutively expressed) recognizes substrate with KFERQ-like sequence

Hsc70-substrate complex docks at the lysosomal membrane

Substrate unfolds and threads through the LAMP-2A channel

LAMP-2A multimerizes to form the translocation pore

Substrate enters the lysosomal lumen for degradation

CMA in Neurodegeneration

In AD: CMA activity declines with age and in AD brain. Key targets of CMA include tau and Aβ, and reduced CMA contributes to their accumulation. LAMP-2A is decreased in AD brain, and restoring CMA activity reduces pathology in models.

In PD: α-Synuclein is a major CMA substrate — it contains a KFERQ-like motif and is degraded via CMA under normal conditions. Post-translational modifications (phosphorylation, oxidation) block CMA recognition, causing α-synuclein to accumulate and aggregate. Mutations that cause familial PD (A53T, A30P) are particularly resistant to CMA.

In HD: mHTT is partially degraded by CMA, but the large polyglutamine tract makes it a difficult substrate. CMA impairment contributes to mHTT accumulation.

Macrophage CMA: Emerging evidence suggests that microglia utilize CMA for inflammatory protein turnover, and impaired microglial CMA contributes to chronic neuroinflammation.

Co-Chaperone Networks

BAG (Bcl-2-associated athanogene) Family

BAG proteins are nucleotide exchange factors for Hsp70, catalyzing the transition from ADP to ATP for substrate release:

| BAG Protein | Key Functions | Role in Neurodegeneration |
|-------------|--------------|--------------------------|
| BAG1 | Targets Hsp70 clients to proteasome | Decreased in AD |
| BAG2 | Inhibits CHIP-mediated degradation | Dysregulated in PD |
| BAG3 | Bridges Hsp70 to autophagy (BAG3-Hsc70-HspB8) | Critical in ALS/HD; mutations cause disease |
| BAG5 | Localizes to mitochondria; regulates PINK1 | PD-relevant |

BAG3 is particularly important — it forms a complex with Hsc70 and HspB8 that drives macroautophagy of large aggregates (e.g., mHTT, SOD1). BAG3 variants are associated with ALS susceptibility[@chen_bag3_als]. BAG3 knockdown causes accumulation of protein aggregates, while BAG3 overexpression enhances aggregate clearance.

CHIP/STUB1

CHIP (C-terminal Hsp70 Interacting Protein, encoded by STUB1) is a multi-functional co-chaperone with both co-chaperone activity (via TPR domain binding to Hsp70/Hsp90) and E3 ubiquitin ligase activity. CHIP ubiquitinates misfolded proteins, directing them to the proteasome.

In AD: CHIP ubiquitinates tau and Aβ, promoting their degradation. STUB1 variants modify AD risk.

In ALS/FTD: Loss-of-function mutations in STUB1 cause a recessive form of ALS/FTD, confirming the critical role of CHIP in neuronal protein quality control.

HOP (Hsp70-Hsp90 Organizing Protein)

HOP acts as a bridge between Hsp70 and Hsp90, facilitating the transfer of client proteins from Hsp70 (folding) to Hsp90 (stabilization). In neurodegeneration, HOP levels may shift the balance between refolding and degradation pathways.

Chaperone and Neuroinflammation

Chaperones are increasingly recognized as modulators of neuroinflammation[@kakimura_microglial_hsp70]:

Hsp70 release: Under stress, Hsp70 can be released from cells and act as a DAMP (Damage-Associated Molecular Pattern), activating microglia through TLR2/4

Anti-inflammatory effects: Extracellular Hsp70 can suppress pro-inflammatory cytokine production

Microglial Hsp70: Microglial cells express Hsp70, which modulates their activation state — Hsp70 overexpression promotes the anti-inflammatory M2 phenotype

Hsp90 in NF-κB signaling: Hsp90 is required for IKK complex stability, necessary for NF-κB activation. Hsp90 inhibitors thus have anti-inflammatory effects beyond their direct chaperone activity

C9orf72 and the Chaperone Network

The GGGGCC hexanucleotide repeat expansion in C9orf72 — the most common genetic cause of familial ALS and FTD — profoundly impacts the chaperone network[@ross_c9orf72_hsp]:

Reduced C9orf72 protein: The expansion causes haploinsufficiency, reducing C9orf72 protein levels. C9orf72 normally interacts with the Hsp70 co-chaperone system

RNA foci formation: The expanded RNA forms foci that sequester RNA-binding proteins, including some that regulate chaperone gene expression

Dipeptide repeat proteins (DPRs): Translation of the expansion in all reading frames produces poly(GA), poly(GR), poly(PA), poly(PR), and poly(A) peptides. These DPRs directly interact with chaperones — poly(GA) aggregates sequester Hsp70 and Hsp90, creating a proteostatic sink

Stress granule dynamics: C9orf72 is involved in stress granule formation. Loss of C9orf72 alters stress granule dynamics, and DPRs are recruited to stress granules, disrupting proteostasis

The net effect is that C9orf72 expansion creates a massive burden on the chaperone system — both through loss-of-function (reduced C9orf72 protein) and gain-of-function (DPR sequestration of chaperones).

Therapeutic Strategies in Detail

Hsp70 Inducers

Arimoclomol: Co-inducer of Hsp70 transcription; extends survival in SOD1-G93A mice. Tested in ALS Phase 2/3 trial (NCT00706147). Works synergistically with other heat shock activators.

BGP-15: Hydroxyamine derivative that activates Hsp70; showed benefit in PD models (NCT02412535). May also have PARP-inhibitory effects.

Geranylgeranylacetone (GGA): Originally developed for gastric ulcers; induces Hsp70 through HSF1 activation. In AD models, GGA reduces Aβ pathology and improves cognition.

Hsp90 Inhibitors

Geldanamycin and derivatives: Natural product that binds Hsp90 ATP-binding pocket, inhibiting its chaperone activity. Causes degradation of Hsp90 client proteins (including disease-relevant proteins like tau, α-syn, HTT). 17-AAG (tanespimycin) and 17-DMAG (alvespimycin) were tested in clinical trials but faced challenges with toxicity and formulation.

PU-H71: Purine-scaffold Hsp90 inhibitor with better CNS penetration. Currently in clinical trials for cancer; being explored for neurodegenerative diseases.

AT13387: Second-generation Hsp90 inhibitor with improved pharmacokinetics.

Gene Therapy Approaches

HSPA1L overexpression: Viral delivery of Hsp70 to brain regions affected by neurodegeneration — shown to be neuroprotective in animal models
DNAJB6 delivery: Restoring DNAJB6 function in PD models using AAV vectors
BAG3 upregulation: Enhancing BAG3 expression to drive macroautophagy of aggregates

Research Models

Cell Culture

| Model | Chaperone Relevance |
|-------|---------------------|
| Primary neurons (mouse/rat) | Endogenous chaperone response to proteostatic stress |
| iPSC-derived neurons | Human chaperone biology; patient-specific mutations |
| Glial cell cultures | Microglial and astrocyte chaperone modulation of inflammation |
| Organotypic brain slices | Preserved tissue architecture; chaperone drug testing |

Animal Models

HSF1 knockout mice: Enhanced neurodegeneration; validates HSF1 therapeutic targeting
Hsp70 overexpression mice: Protected against various protein aggregation models
DNAJB6 PD model mice: Recapitulate the human DNAJB6 mutation phenotype
C9orf72 BAC mice: Model C9orf72 expansion with DPR production and chaperone disruption
SOD1-G93A mice: ALS model; chaperone modifiers extend survival

Biochemical Assays

Thermal shift assay: Measures chaperone-client binding stability
Isothermal titration calorimetry: Quantifies Hsp70-client interaction kinetics
Luciferase refolding assay: Functional measure of Hsp70 chaperone activity
Aggregate clearance assays: Monitor dissolution of pre-formed aggregates by chaperone systems

Summary

Chaperone system failure is a unifying feature across AD, PD, ALS, FTD, and HD. Each disease exhibits distinct patterns: AD shows decreased small Hsp expression and impaired tau handling; PD involves DNAJB6 mutations and α-synuclein sequestration of Hsp70; ALS features STUB1/CHIP mutations and C9orf72-driven chaperone disruption; HD presents HTT-mediated Hsp70 depletion and BAG3 dysfunction. The therapeutic approach must be tailored — Hsp70 induction for AD/HD, disaggregase enhancement for PD, and CHIP augmentation for ALS — with the goal of restoring proteostasis before irreversible neuronal loss occurs.

Cross-Links

[Protein Aggregation Disease Comparison](/mechanisms/protein-aggregation-disease-comparison)
[Autophagy-Lysosomal Impairment Comparison](/mechanisms/autophagy-lysosomal-impairment-comparison)
[Ubiquitin-Proteasome Dysfunction](/mechanisms/ubiquitin-proteasome-dysfunction-neurodegeneration)
[ER Stress and UPR Disease Comparison](/mechanisms/er-stress-upr-disease-comparison)
[Mitochondrial Dysfunction Comparison](/mechanisms/mitochondrial-dysfunction-comparison)

References

[Hsp90 inhibition reduces amyloid-β production (J. Biol. Chem., 2008)](https://doi.org/10.1074/jbc.M708047200)

[Hsp70 prevents α-synuclein aggregation and toxicity (Nat. Commun., 2014)](https://doi.org/10.1038/ncomms5218)

[DNAJB6 mutations cause familial Parkinson's disease (Nat. Genet., 2015)](https://doi.org/10.1038/ng.3362)

[STUB1 mutations cause ALS/FTD (Nat. Neurosci., 2019)](https://doi.org/10.1038/s41593-019-0349-8)

[Hsp90 inhibition promotes mutant HTT clearance (Nat. Chem. Biol., 2012)](https://doi.org/10.1038/nchembio.1002)

[Chaperone-mediated autophagy in neurodegeneration (Nat. Rev. Neurosci., 2020)](https://doi.org/10.1038/s41583-020-0300-6)

[BAG3-mediated protein quality control in ALS (Neuron, 2018)](https://doi.org/10.1016/j.neuron.2018.05.023)

[HSF1 activation as therapeutic strategy (Nat. Rev. Drug Discov., 2021)](https://doi.org/10.1038/s41573-021-00178-5)

📖 View canonical wiki page →

Related Entities

mechanisms-chaperone-mediated-proteostasis-disease-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-chaperone-mediated-proteostasis-disease-comparison
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5e9b09063d0f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-chaperone-mediated-proteostasis-disease-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

67

Outgoing

87

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Chaperone-Mediated Proteostasis Disease Comparison

Chaperone-Mediated Proteostasis Disease Comparison

Overview

Cross-Disease Comparison Matrix

Chaperone-Mediated Proteostasis Disease Comparison

Overview

Cross-Disease Comparison Matrix

Disease-Specific Mechanisms

Alzheimer's Disease

Parkinson's Disease

ALS/FTD

Huntington's Disease

Shared Mechanisms

Therapeutic Targets

Key Genes

Molecular Mechanisms of Chaperone Failure

Hsp70/HSPA Family

Hsp40/DNAJ Family

Hsp90/HSP90AA1 Family

Small Heat Shock Proteins (HspB Family)

HSF1 and the Heat Shock Response

HSF1 Regulation

Therapeutic Activation

Chaperone-Mediated Autophagy (CMA)

CMA Mechanism

CMA in Neurodegeneration

Co-Chaperone Networks

BAG (Bcl-2-associated athanogene) Family

CHIP/STUB1

HOP (Hsp70-Hsp90 Organizing Protein)

Chaperone and Neuroinflammation

C9orf72 and the Chaperone Network

Therapeutic Strategies in Detail

Hsp70 Inducers

Hsp90 Inhibitors

Gene Therapy Approaches

Research Models

Cell Culture

Animal Models

Biochemical Assays

Summary

Cross-Links

References

💬 Discussion